Recent Advances with Chemotherapy for NSCLG: The ECOG Experience

ONCOLOGY

Volumn 12, Issue 1 SUPPL. 2, 1998, Pages 67-70

  Johnson, David H ^a   Chang, Alex Y ^b   Ettinger, David S ^c   Kim, Kyung Mann ^d   Bonomi, Philip ^e  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; AMONAFIDE; CARBOPLATIN; CISPLATIN; ECHINOMYCIN; ETOPOSIDE; GALLIUM NITRATE; HOMOHARRINGTONINE; IPROPLATIN; MITOMYCIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PODOPHYLLOTOXIN; TENIPOSIDE; TRIMETREXATE; TRIMETREXATE GLUCURONATE; VINBLASTINE; VINBLASTINE SULFATE; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; ORAL DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; FORECASTING; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 0031914644     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small-cell lung cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 4:702-709, 1986.
2. Bonorni PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy vs single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer; A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989.
3. Eagan R, Fleming T, Schoonover V: Evaluation of response criteria in advanced lung cancer. Cancer 44:1125-1128, 1979.
4. Herschorn S, Hanley J, Wolkove N, et al: Measurability of non-small-cell lung cancer on chest radiographs. J Clin Oncol 4:1184-1190, 1986.
5. Hazuka MB, Bunn PA: Controversies in the nonsurgical treatment of stage III non-small-cell lung cancer. Am Rev Respir Dis 145:967-977, 1992.
6. Chang AY, Tu ZN, Smith JL, et al: Phase II trial of gallium nitrate, amonafide and temposide in metastatic non-small-cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs 13-137-141, 1995
7. Chang AY, Tu ZN, Bryan GT, et al: Phase II study of echinomycin in the treatment of renal cell carcinoma: ECOG study E2885. Invest New Drugs 12:151-153, 1994.
8. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993.
9. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
10. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993.
11. Rowinsky EK, Donehower RC: Taxol: Twenty years later, the story unfolds. J Natl Cancer Inst 83:1778-1781, 1991.
12. Rowinsky EK, Wright M, Monsarrat B, et al: Taxol: Pharmacology, metabolism and clinical implications. Cancer Sun 17:283-304, 1993.
13. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) cisplatin (C) vs Taxol (T) with cisplatin-G-CSF (G) vs Taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial (abstract). Proc Am Soc Clin Oncol 15:382, 1996.
14. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
15. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase III trial of cisplatin (CDDP) vs CDDP plus Navelbine (NVB) in treatment of advanced non-small-cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308) (abstract). Proc Am Soc Clin Oncol 15:374, 1996.
16. Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxol (Taxotere) and cisplatin in advanced non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 14:350, 1995.
17. Cole JT, Gralla RJ, Marques CB, et al: Phase I-II study of cisplatin + docetaxol (Taxotere) in non-small-cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 14:357, 1995.
18. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): A phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol 13:1860-1870, 1995.
19. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer-A phase II trial. J Clin Oncol 14:2054-2060, 1996.
20. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer-A phase II study. J Clin Oncol 15:297-303, 1997.
21. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin-Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997.